Health Care · S&P 500
Incyte
A U.S. biopharmaceutical company that develops and markets oncology and autoimmune disease treatments. S&P 500 constituent. Sector: Health Care (Biotechnology). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
INCY Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-07-10'21-15.6%'22+9.4%'23-21.8%'24+10%'25+43%YTD+18.2%
Money in ▸·
Incyte~$4.2B
▸ Money out·
Financials & Segments
- Total revenue · ~$4.2B (FY2024)
- Segments · Jakafi (ruxolitinib) · Opzelura · Other products & royalties
Revenue from
No refined links yet.
Pays to
No refined links yet.